US20050131513A1 - Stent catheter with a permanently affixed conductor - Google Patents

Stent catheter with a permanently affixed conductor Download PDF

Info

Publication number
US20050131513A1
US20050131513A1 US10/738,812 US73881203A US2005131513A1 US 20050131513 A1 US20050131513 A1 US 20050131513A1 US 73881203 A US73881203 A US 73881203A US 2005131513 A1 US2005131513 A1 US 2005131513A1
Authority
US
United States
Prior art keywords
stent
conductor
catheter
balloon
assembly according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/738,812
Inventor
Randy Myers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cook Inc
Original Assignee
Cook Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cook Inc filed Critical Cook Inc
Priority to US10/738,812 priority Critical patent/US20050131513A1/en
Assigned to COOK INCORPORATED reassignment COOK INCORPORATED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MYERS, RANDY JOE
Priority to AU2004305488A priority patent/AU2004305488B2/en
Priority to PCT/US2004/035632 priority patent/WO2005060870A2/en
Priority to DK04796535.5T priority patent/DK1699384T3/en
Priority to JP2006545338A priority patent/JP4563402B2/en
Priority to EP04796535.5A priority patent/EP1699384B1/en
Priority to CA2548761A priority patent/CA2548761C/en
Publication of US20050131513A1 publication Critical patent/US20050131513A1/en
Priority to US12/013,927 priority patent/US7879387B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/95Instruments specially adapted for placement or removal of stents or stent-grafts
    • A61F2/958Inflatable balloons for placing stents or stent-grafts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08Materials for coatings
    • A61L31/082Inorganic materials
    • A61L31/088Other specific inorganic materials not covered by A61L31/084 or A61L31/086
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067Means for introducing or releasing pharmaceutical products into the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606Coatings

Definitions

  • the present invention relates generally to medical devices and particularly to a catheter used to implant stents which has a permanently affixed conductor.
  • stents to treat various organs, such as the vascular system, colon, biliary tract, urinary tract, esophagus, trachea and the like, has become common.
  • stents are useful in treating blockages, occlusions, narrowing ailments and other similar problems that restrict flow through a passageway.
  • Stents are useful for numerous medical treatments of various vessels throughout the vascular system, including both coronary vessels and peripheral vessels (e.g., carotid, brachial, renal, iliac and femoral).
  • coronary vessels e.g., carotid, brachial, renal, iliac and femoral
  • peripheral vessels e.g., carotid, brachial, renal, iliac and femoral.
  • stents in coronary vessels has drawn particular attention from the medical community due to the commonality of heart problems caused by stenosis (i.e., narrowing of a vessel).
  • stenosis may occur for a variety of reasons, one of the most common causes of coronary stenosis results from the buildup of atherosclerotic plaques along the lumen of the vessel. The resulting coronary stenosis restricts blood flow through the vessel, which eventually can lead to a dangerously increased risk of heart attacks.
  • PTA percutaneous transluminal angioplasty
  • restenosis i.e., re-narrowing
  • Restenosis may occur for a variety of reasons, such as collapsing of the vessel wall or growth of cellular tissue.
  • restenosis may occur due to damage caused to the vessel lining during balloon expansion and vessel dilating.
  • the vessel attempts to grow new intima tissue to repair the damage.
  • This tendency of vessels to regrow new tissue is referred to as neointimal hyperplasia.
  • the effect of this response results in a re-narrowing of the vessel.
  • restenosis is not completely predictable and may occur either abruptly soon after the PTA procedure due to vessel collapse or may occur slowly over a longer period of time due to other reasons.
  • stents are made of metal or other synthetic materials, thereby providing a tubular support structure that radially supports the inner wall of the vessel.
  • stainless steel e.g., 316L SS and 304 SS
  • Nitinol e.g., 316L SS and 304 SS
  • stents are designed with a pattern of openings formed in the support structure that permits the stent to radially expand from a small diameter to a larger diameter.
  • stents are now commonly used in conjunction with conventional PTA procedures by positioning the stent within the portion of the vessel that has been dilated by the balloon and radially expanding the stent against the inner wall of the vessel to permanently implant the stent.
  • the expectation of this revised PTA procedure is that the support structure of the implanted stent will mechanically prevent the vessel from collapsing back to its original narrowed condition.
  • Balloon-expandable stents are generally made from ductile materials that plastically deform relatively easily. In the case of stents made from metal, 316L stainless steel that has been annealed is a common choice for this type of stent.
  • One common procedure for implanting a balloon-expandable stent involves mounting the stent circumferentially on the balloon prior to threading the balloon-tipped catheter to the narrowed vessel portion that is to be treated. When the balloon is positioned at the narrowed vessel portion and expanded, the balloon simultaneously dilates the vessel and also radially expands the stent into the dilated portion.
  • a second common category of stents is referred to as self-expandable stents.
  • Self-expandable stents are generally made of shape memory materials that act like a spring. Typical metals used in this type of stent include Nitinol and 304 stainless steel.
  • a common procedure for implanting a self-expandable stent involves a two-step process. First, the narrowed vessel is dilated with the balloon as described above. Second, the stent is implanted into the dilated vessel portion. To accomplish the stent implantation, the stent is installed on the end of a catheter in a compressed, small diameter state and is retained in the small diameter by inserting the stent into the lumen of the catheter or by other means.
  • the stent is then guided to the balloon-dilated portion and is released from the catheter and allowed to radially spring outward to an expanded diameter until the stent contacts and presses against the vessel wall.
  • self-expandable stents have been more commonly used in peripheral vessels than in coronary vessels due to the shape memory characteristic of the metals used in these stents.
  • One advantage of self-expandable stents for peripheral vessels is that traumas from external sources do not permanently deform the stent. Instead, the stent may temporarily deform during an unusually harsh trauma but will spring back to its expanded state once the trauma is relieved.
  • Self-expandable stents are often considered to be less preferred for coronary vessels as compared to balloon-expandable stents.
  • balloon-expandable stents can be precisely sized to a particular vessel diameter and shape since the ductile metal that is used can be plastically deformed to a desired size and shape.
  • self-expandable stents are designed with a particular expansible range. Thus, after being installed self-expandable stents continue to exert pressure against the vessel wall.
  • restenosis still remains a problem.
  • one cause of restenosis is neointimal hyperplasia which may result from damage to the vessel wall. This cause of neointimal hyperplasia remains a problem even when a stent is used.
  • the synthetic materials that are usually used in stents may also contribute to neointimal hyperplasia. The cause of this problem is the body's tendency to grow new living tissues around and over newly implanted foreign objects. Thus, despite the mechanical support structure provided by the stent, restenosis remains a problem.
  • a stent is provided by the manufacturer as part of a pre-assembled package.
  • the package may include a catheter, a balloon formed at the end of the catheter, and a drug-coated stent mounted onto the balloon.
  • the package may include a catheter, a mounting apparatus for retaining and releasing the stent, and a drug-coated stent mounted on the apparatus.
  • One method that may be used to manufacture the above-described stent assemblies involves coating the stent first in a separate step and then mounting the coated stent onto the balloon or other mounting apparatus.
  • Common coating processes include dipping, spraying and painting the drug onto the stent.
  • these methods suffer from numerous problems.
  • One problem is the difficulty of mounting the coated stent onto the catheter without damaging the coating that has been applied.
  • many conventional coating processes are difficult to control and apply an uneven coating on the stent.
  • the stent may be coated after being mounted onto the catheter.
  • this method has not been perfected.
  • conventional coating processes are difficult to control and apply uneven coatings. This can be an even more significant problem when the coating is applied to a stent mounted to a catheter since the coating inevitably ends up coating the catheter, balloon and/or mounting apparatus also.
  • Precisely controlling the application of coatings on stents is important for a number of reasons. For example, in the case of drug coatings in particular, it is important to ensure that the drug is applied as evenly as possible on the specific surfaces where the coating is needed. This ensures a uniform physiological response to the drug after the stent is implanted. Another important reason for precisely controlling the application of coatings is the high cost of many coatings. Typically, in the case of drug coatings, the cost of the drug per unit volume can be very expensive. Therefore, the drug should be applied as precisely as possible to the surfaces of the stent where the effectiveness of the drug can be maximized. Thus, by minimizing waste during the coating process, the overall cost of the stent assembly may be reduced.
  • a stent assembly is provided with a conductor that is permanently affixed to a catheter.
  • the conductor is applied to the exterior of the catheter using conductive ink.
  • the conductor extends longitudinally along the catheter and contacts the stent.
  • One advantage of the conductor is that the stent assembly may be coated with drugs or other coatings using an electrostatic coating process. During the electrostatic coating process, the conductor is grounded or connected to an opposite electrical charge, thereby providing electrical attraction between charged coating particles and the stent. Additional details and advantages are further described below.
  • FIG. 1 is a side view of a catheter with a balloon and stent located at a distal end thereof, showing an electrostatic coating process
  • FIG. 2 is a close-up side view of a portion of the catheter, showing the balloon and the stent with a conductor extending along a portion thereof.
  • a stent assembly 10 is provided for use in percutaneous transluminal angioplasty (“PTA”) procedures.
  • the stent assembly 10 is provided as a pre-assembled package with the stent 16 mounted onto a balloon 14 which is formed at the end of a catheter 12 .
  • the principles taught herein may also be adapted to a self-expandable stent assembly in which the stent is mounted on a mounting apparatus that selectively retains and releases the stent.
  • the catheter 12 includes a conductor 18 that is permanently affixed to the catheter 12 .
  • the conductor 18 is affixed to the outer surface of the catheter 12 and extends longitudinally along a portion of the catheter 12 .
  • the conductor 18 may extend along the full length of the catheter 12 , or the conductor 18 may extend as little as an inch or less along the catheter 12 .
  • the conductor 18 may also extend along a portion of the balloon 14 .
  • the conductor 18 contacts an inner surface of the stent 16 . Since the stent 16 is metallic, an electrical connection is made between the stent 16 and the conductor 18 .
  • the conductor 18 comprises conductive ink that is applied to the exterior of the catheter 12 and balloon 14 as a stripe.
  • conductive ink that may be used is a silver-based epoxy ink. Conductive ink of this type may be obtained from Creative Metals Incorporated as product number CMI 119-21 and referred to as Printable Solvent Resistant Electrically Inductive Ink.
  • numerous other types of conductive ink may also be used, such as platinum-based, gold-based and copper-based inks.
  • Non-epoxy inks may also be used, such as urethane inks.
  • any compound which may be applied in a liquid or gel form and is capable of conducting an electrical current after application may be considered conductive ink.
  • the conductor 18 may also comprise any other conductive material, such as conductive polymers.
  • the conductive ink may be applied to the catheter 12 and balloon 14 with a variety of printing processes, such as pad printing, ink jet printing, spraying, marker striping, painting or other like processes.
  • pad printing is preferred since it is relatively easy with this process to apply a consistent ink stripe on the catheter 12 and balloon 14 .
  • An advantage of the conductor 18 is that coatings 24 may be applied to the stent 16 with electrostatic coating processes instead of conventional coating processes.
  • an electrostatic spray nozzle 20 charges the coating material and dispenses charged coating particles 22 towards and around the stent 16 .
  • Examples of electrostatic coating processes that may be used are described in U.S. Pat. Nos. 4,749,125; 5,165,601; 5,086,973 and 5,332,154, which are all hereby incorporated by reference herein.
  • Other electrostatic coating processes may also be used, and any coating process that electrically charges the coating material may be adapted for coating the stent 16 .
  • An electrical charge is also applied to the conductor 18 by either grounding the conductor 18 or by connecting the conductor 18 to a charge that is opposite to the charge of the coating particles 22 .
  • the charged coating particles 32 become electrically attracted to the stent 16 .
  • the coating particles 22 are drawn to the surfaces of the stent 16 and adhere to the stent 16 once contact is made.
  • the coating 24 that results is considerably more consistent and uniform than coatings applied by conventional processes.
  • the conductor 18 may be grounded 26 in any manner known to those in the art.
  • the conductor 18 may be grounded 26 by the fixture that holds the stent assembly 10 during the coating process. Collets or other known arrangements may be readily adapted to serve as a ground 26 for the conductor 18 .
  • the conductor 18 may be connected to an opposite charge in any manner known in the art.
  • Electrostatic coating offers significant improvements over conventional coating processes, such as dipping, spraying and painting.
  • One of the benefits of electrostatic coating is that the application of the coating 24 can be precisely controlled.
  • a precise amount of the therapeutic agent can be applied uniformly over the stent 16 without the inconsistencies and waste of conventional processes. This is particularly helpful when typical anti-restenosis drugs are used since these drugs can be especially expensive.
  • Other coatings 24 may also be applied to the stent 16 , such as hydrophilic coatings, with similar benefits.
  • the stent 16 there are also several advantages of coating the stent 16 after the stent 16 has been mounted to the catheter 16 as compared to separately coating the stent 16 .
  • One benefit is that damage to the coating 24 can be minimized since the manufacturer does not need to handle an already coated stent when mounting the stent 16 to the balloon 14 .
  • Another benefit is that the coating 24 is applied only to the outside surface of the stent 16 instead of being applied partially to the inside of the stent 16 as may occur when the stent 16 is coated separately. In the case of anti-restenosis drugs, this is a more efficient result since the anti-restenosis drug is primarily needed on the exterior surfaces of the stent 16 where the stent 16 contacts the vessel wall after implantation.
  • the electrically charged coating particles 22 will be attracted primarily to the metallic stent 16 as compared to the non-metallic balloon, some of the drug coating 24 (or any other coating used) can be expected to pass through the openings in the stent 16 and adhere to the balloon 14 instead of the stent 16 . However, even these balloon-coated portions may provide some benefits since these coated portions may contact the vessel wall during balloon expansion, thereby being transferred to the vessel wall.
  • a further advantage of the conductor 18 is that it is permanently affixed to the catheter 12 .
  • One alternative approach that could be used to electrostatically coat a stent 16 involves positioning a loose ground wire under or adjacent the stent 16 to make an electrical connection. However, this approach is undesirable because the loose wire may be inadvertently left attached to the stent assembly 10 after coating. This could have serious consequences if the loose wire is not removed prior to a surgeon using the stent assembly 10 in a PTA procedure. In addition, even when the wire is properly removed during manufacturing of the stent assembly 10 , the removal step could damage the stent assembly 10 . One possible risk is that the wire might puncture the balloon 14 . In addition, removal of the wire may dislodge some of the coating 24 .
  • the conductor may also provide other advantages as well.
  • the conductor 18 may improve visualization of the catheter 12 and stent assembly 10 during implantation by showing up more distinctly in imaging devices.
  • the conductor 18 could be used during PTA or other surgical procedures to supply electrical current to the internal area of the body that is being treated.

Abstract

A stent assembly is provided. A conductor which is permanently affixed to a catheter contacts a stent mounted on the catheter. Conductive ink applied to the catheter may be used as the conductor. A method of coating the stent is also provided. In the method, an electrical charge is applied to the conductor. The stent is then coated using an electrostatic coating process.

Description

    BACKGROUND
  • The present invention relates generally to medical devices and particularly to a catheter used to implant stents which has a permanently affixed conductor.
  • The use of stents to treat various organs, such as the vascular system, colon, biliary tract, urinary tract, esophagus, trachea and the like, has become common. Typically, stents are useful in treating blockages, occlusions, narrowing ailments and other similar problems that restrict flow through a passageway.
  • One common medical treatment in which stents are used involves implanting an endovascular stent into the vascular system. Stents are useful for numerous medical treatments of various vessels throughout the vascular system, including both coronary vessels and peripheral vessels (e.g., carotid, brachial, renal, iliac and femoral). However, the use of stents in coronary vessels has drawn particular attention from the medical community due to the commonality of heart problems caused by stenosis (i.e., narrowing of a vessel).
  • Although stenosis may occur for a variety of reasons, one of the most common causes of coronary stenosis results from the buildup of atherosclerotic plaques along the lumen of the vessel. The resulting coronary stenosis restricts blood flow through the vessel, which eventually can lead to a dangerously increased risk of heart attacks.
  • The medical community has attempted to address coronary stenosis (along with the many other passageway problems that patients suffer from) with various versions of percutaneous transluminal angioplasty (“PTA”). Fundamentally, PTA involves inserting a balloon-tipped catheter into a vessel and threading the catheter to the narrowed portion to be treated. The balloon is then expanded at the narrowed portion by pumping saline through the catheter to the balloon. As a result, the balloon expands, contacts the inner vessel wall, and forces the vessel to dilate. The balloon is then deflated and retracted from the vessel.
  • One problem that has been encountered with typical PTA procedures is restenosis (i.e., re-narrowing) of the vessel. Restenosis may occur for a variety of reasons, such as collapsing of the vessel wall or growth of cellular tissue. For example, restenosis may occur due to damage caused to the vessel lining during balloon expansion and vessel dilating. As a result of the damage caused to the intima layers of the vessel, the vessel attempts to grow new intima tissue to repair the damage. This tendency of vessels to regrow new tissue is referred to as neointimal hyperplasia. The effect of this response results in a re-narrowing of the vessel. However, restenosis is not completely predictable and may occur either abruptly soon after the PTA procedure due to vessel collapse or may occur slowly over a longer period of time due to other reasons.
  • One approach the medical community has tried in order to overcome the problems with restenosis is to use stents in conjunction with the above-described PTA procedure. Traditionally, stents are made of metal or other synthetic materials, thereby providing a tubular support structure that radially supports the inner wall of the vessel. Although other materials are possible and are sometimes used, the most common materials now used in stents are stainless steel (e.g., 316L SS and 304 SS) and Nitinol. Typically, stents are designed with a pattern of openings formed in the support structure that permits the stent to radially expand from a small diameter to a larger diameter. Accordingly, stents are now commonly used in conjunction with conventional PTA procedures by positioning the stent within the portion of the vessel that has been dilated by the balloon and radially expanding the stent against the inner wall of the vessel to permanently implant the stent. The expectation of this revised PTA procedure is that the support structure of the implanted stent will mechanically prevent the vessel from collapsing back to its original narrowed condition.
  • Although stent designs and implantation procedures vary widely, two categories are common.
  • The first of these two categories may be referred to as balloon-expandable stents. Balloon-expandable stents are generally made from ductile materials that plastically deform relatively easily. In the case of stents made from metal, 316L stainless steel that has been annealed is a common choice for this type of stent. One common procedure for implanting a balloon-expandable stent involves mounting the stent circumferentially on the balloon prior to threading the balloon-tipped catheter to the narrowed vessel portion that is to be treated. When the balloon is positioned at the narrowed vessel portion and expanded, the balloon simultaneously dilates the vessel and also radially expands the stent into the dilated portion. The balloon and the catheter are then retracted, leaving the expanded stent permanently implanted at the desired location. Ductile metal lends itself to this type of stent since the stent may be compressed by plastic deformation to a small diameter when mounted onto the balloon. When the balloon is then expanded in the vessel, the stent is once again plastically deformed to a larger diameter to provide the desired radial support structure. Traditionally, balloon-expandable stents have been more commonly used in coronary vessels than in peripheral vessels due to the deformable nature of these stents. One reason for this is that peripheral vessels tend to experience frequent traumas from external sources (e.g., impacts to a person's arms, legs, etc.) which are transmitted through the body's tissues to the vessel. In the case of peripheral vessels, there is an increased risk that an external trauma could cause a balloon-expandable stent to once again plastically deform in unexpected ways with potentially severe and/or catastrophic results. In the case of coronary vessels, however, this risk is minimal since coronary vessels rarely experience traumas transmitted from external sources.
  • A second common category of stents is referred to as self-expandable stents. Self-expandable stents are generally made of shape memory materials that act like a spring. Typical metals used in this type of stent include Nitinol and 304 stainless steel. A common procedure for implanting a self-expandable stent involves a two-step process. First, the narrowed vessel is dilated with the balloon as described above. Second, the stent is implanted into the dilated vessel portion. To accomplish the stent implantation, the stent is installed on the end of a catheter in a compressed, small diameter state and is retained in the small diameter by inserting the stent into the lumen of the catheter or by other means. The stent is then guided to the balloon-dilated portion and is released from the catheter and allowed to radially spring outward to an expanded diameter until the stent contacts and presses against the vessel wall. Traditionally, self-expandable stents have been more commonly used in peripheral vessels than in coronary vessels due to the shape memory characteristic of the metals used in these stents. One advantage of self-expandable stents for peripheral vessels is that traumas from external sources do not permanently deform the stent. Instead, the stent may temporarily deform during an unusually harsh trauma but will spring back to its expanded state once the trauma is relieved. Self-expandable stents, however, are often considered to be less preferred for coronary vessels as compared to balloon-expandable stents. One reason for this is that balloon-expandable stents can be precisely sized to a particular vessel diameter and shape since the ductile metal that is used can be plastically deformed to a desired size and shape. In contrast, self-expandable stents are designed with a particular expansible range. Thus, after being installed self-expandable stents continue to exert pressure against the vessel wall.
  • However, even when a stent is used in conjunction with conventional PTA procedures, restenosis still remains a problem. As discussed above, one cause of restenosis is neointimal hyperplasia which may result from damage to the vessel wall. This cause of neointimal hyperplasia remains a problem even when a stent is used. In addition, the synthetic materials that are usually used in stents may also contribute to neointimal hyperplasia. The cause of this problem is the body's tendency to grow new living tissues around and over newly implanted foreign objects. Thus, despite the mechanical support structure provided by the stent, restenosis remains a problem.
  • One approach that has been offered to address the problem of restenosis has been to coat stents with drugs that are designed to inhibit cellular growth. Although many such drugs are known, common examples of these types of drugs include Paclitaxel, Sirolimus and Everolimus. However, despite the benefits of these types of drugs, numerous problems still exist with the current methods that are used to apply these and other coatings to stents.
  • Typically, a stent is provided by the manufacturer as part of a pre-assembled package. For example, in the case of a balloon-expandable stent, the package may include a catheter, a balloon formed at the end of the catheter, and a drug-coated stent mounted onto the balloon. In the case of a self-expandable stent, the package may include a catheter, a mounting apparatus for retaining and releasing the stent, and a drug-coated stent mounted on the apparatus.
  • One method that may be used to manufacture the above-described stent assemblies involves coating the stent first in a separate step and then mounting the coated stent onto the balloon or other mounting apparatus. Common coating processes include dipping, spraying and painting the drug onto the stent. However, these methods suffer from numerous problems. One problem is the difficulty of mounting the coated stent onto the catheter without damaging the coating that has been applied. In addition, many conventional coating processes are difficult to control and apply an uneven coating on the stent. Moreover, when the stent is coated separately, it is difficult to avoid coating at least part of both the inside and outside surfaces of the stent.
  • Alternatively, the stent may be coated after being mounted onto the catheter. However, this method has not been perfected. As mentioned, conventional coating processes are difficult to control and apply uneven coatings. This can be an even more significant problem when the coating is applied to a stent mounted to a catheter since the coating inevitably ends up coating the catheter, balloon and/or mounting apparatus also.
  • Precisely controlling the application of coatings on stents is important for a number of reasons. For example, in the case of drug coatings in particular, it is important to ensure that the drug is applied as evenly as possible on the specific surfaces where the coating is needed. This ensures a uniform physiological response to the drug after the stent is implanted. Another important reason for precisely controlling the application of coatings is the high cost of many coatings. Typically, in the case of drug coatings, the cost of the drug per unit volume can be very expensive. Therefore, the drug should be applied as precisely as possible to the surfaces of the stent where the effectiveness of the drug can be maximized. Thus, by minimizing waste during the coating process, the overall cost of the stent assembly may be reduced.
  • It is apparent to the inventor that a stent assembly is desired in which coatings may be applied to the stent in a more effective manner than is presently possible. Accordingly, a solution is described more fully below that solves this and other problems.
  • SUMMARY
  • A stent assembly is provided with a conductor that is permanently affixed to a catheter. Preferably, the conductor is applied to the exterior of the catheter using conductive ink. The conductor extends longitudinally along the catheter and contacts the stent. One advantage of the conductor is that the stent assembly may be coated with drugs or other coatings using an electrostatic coating process. During the electrostatic coating process, the conductor is grounded or connected to an opposite electrical charge, thereby providing electrical attraction between charged coating particles and the stent. Additional details and advantages are further described below.
  • BRIEF DESCRIPTION OF SEVERAL VIEWS OF THE DRAWINGS
  • The invention may be more fully understood by reading the following description in conjunction with the drawings in which:
  • FIG. 1 is a side view of a catheter with a balloon and stent located at a distal end thereof, showing an electrostatic coating process; and
  • FIG. 2 is a close-up side view of a portion of the catheter, showing the balloon and the stent with a conductor extending along a portion thereof.
  • DETAILED DESCRIPTION
  • Referring now to the figures, a stent assembly 10 is provided for use in percutaneous transluminal angioplasty (“PTA”) procedures. The stent assembly 10 is provided as a pre-assembled package with the stent 16 mounted onto a balloon 14 which is formed at the end of a catheter 12. Although not shown, the principles taught herein may also be adapted to a self-expandable stent assembly in which the stent is mounted on a mounting apparatus that selectively retains and releases the stent.
  • The catheter 12 includes a conductor 18 that is permanently affixed to the catheter 12. As shown, the conductor 18 is affixed to the outer surface of the catheter 12 and extends longitudinally along a portion of the catheter 12. The conductor 18 may extend along the full length of the catheter 12, or the conductor 18 may extend as little as an inch or less along the catheter 12. The conductor 18 may also extend along a portion of the balloon 14. At one end, the conductor 18 contacts an inner surface of the stent 16. Since the stent 16 is metallic, an electrical connection is made between the stent 16 and the conductor 18.
  • In the preferred embodiment, the conductor 18 comprises conductive ink that is applied to the exterior of the catheter 12 and balloon 14 as a stripe. One type of conductive ink that may be used is a silver-based epoxy ink. Conductive ink of this type may be obtained from Creative Metals Incorporated as product number CMI 119-21 and referred to as Printable Solvent Resistant Electrically Inductive Ink. However, numerous other types of conductive ink may also be used, such as platinum-based, gold-based and copper-based inks. Non-epoxy inks may also be used, such as urethane inks. In general, any compound which may be applied in a liquid or gel form and is capable of conducting an electrical current after application may be considered conductive ink. Moreover, the conductor 18 may also comprise any other conductive material, such as conductive polymers.
  • The conductive ink may be applied to the catheter 12 and balloon 14 with a variety of printing processes, such as pad printing, ink jet printing, spraying, marker striping, painting or other like processes. However, pad printing is preferred since it is relatively easy with this process to apply a consistent ink stripe on the catheter 12 and balloon 14.
  • An advantage of the conductor 18 is that coatings 24 may be applied to the stent 16 with electrostatic coating processes instead of conventional coating processes. As shown in FIG. 1, an electrostatic spray nozzle 20 charges the coating material and dispenses charged coating particles 22 towards and around the stent 16. Examples of electrostatic coating processes that may be used are described in U.S. Pat. Nos. 4,749,125; 5,165,601; 5,086,973 and 5,332,154, which are all hereby incorporated by reference herein. Other electrostatic coating processes may also be used, and any coating process that electrically charges the coating material may be adapted for coating the stent 16. An electrical charge is also applied to the conductor 18 by either grounding the conductor 18 or by connecting the conductor 18 to a charge that is opposite to the charge of the coating particles 22. Thus, the charged coating particles 32 become electrically attracted to the stent 16. As a result, the coating particles 22 are drawn to the surfaces of the stent 16 and adhere to the stent 16 once contact is made. The coating 24 that results is considerably more consistent and uniform than coatings applied by conventional processes. The conductor 18 may be grounded 26 in any manner known to those in the art. For example, the conductor 18 may be grounded 26 by the fixture that holds the stent assembly 10 during the coating process. Collets or other known arrangements may be readily adapted to serve as a ground 26 for the conductor 18. Likewise, the conductor 18 may be connected to an opposite charge in any manner known in the art.
  • Electrostatic coating offers significant improvements over conventional coating processes, such as dipping, spraying and painting. One of the benefits of electrostatic coating is that the application of the coating 24 can be precisely controlled. Thus, in the case of drug coatings, a precise amount of the therapeutic agent can be applied uniformly over the stent 16 without the inconsistencies and waste of conventional processes. This is particularly helpful when typical anti-restenosis drugs are used since these drugs can be especially expensive. Other coatings 24 however may also be applied to the stent 16, such as hydrophilic coatings, with similar benefits.
  • There are also several advantages of coating the stent 16 after the stent 16 has been mounted to the catheter 16 as compared to separately coating the stent 16. One benefit is that damage to the coating 24 can be minimized since the manufacturer does not need to handle an already coated stent when mounting the stent 16 to the balloon 14. Another benefit is that the coating 24 is applied only to the outside surface of the stent 16 instead of being applied partially to the inside of the stent 16 as may occur when the stent 16 is coated separately. In the case of anti-restenosis drugs, this is a more efficient result since the anti-restenosis drug is primarily needed on the exterior surfaces of the stent 16 where the stent 16 contacts the vessel wall after implantation. Although the electrically charged coating particles 22 will be attracted primarily to the metallic stent 16 as compared to the non-metallic balloon, some of the drug coating 24 (or any other coating used) can be expected to pass through the openings in the stent 16 and adhere to the balloon 14 instead of the stent 16. However, even these balloon-coated portions may provide some benefits since these coated portions may contact the vessel wall during balloon expansion, thereby being transferred to the vessel wall.
  • A further advantage of the conductor 18 is that it is permanently affixed to the catheter 12. One alternative approach that could be used to electrostatically coat a stent 16 involves positioning a loose ground wire under or adjacent the stent 16 to make an electrical connection. However, this approach is undesirable because the loose wire may be inadvertently left attached to the stent assembly 10 after coating. This could have serious consequences if the loose wire is not removed prior to a surgeon using the stent assembly 10 in a PTA procedure. In addition, even when the wire is properly removed during manufacturing of the stent assembly 10, the removal step could damage the stent assembly 10. One possible risk is that the wire might puncture the balloon 14. In addition, removal of the wire may dislodge some of the coating 24.
  • The conductor may also provide other advantages as well. For example, the conductor 18 may improve visualization of the catheter 12 and stent assembly 10 during implantation by showing up more distinctly in imaging devices. Moreover, if the conductor 18 is extended along the entire longitudinal length of the catheter 12, the conductor 18 could be used during PTA or other surgical procedures to supply electrical current to the internal area of the body that is being treated.
  • It is now apparent that there are many advantages of the invention provided herein. In addition to the many advantages that have been described, it is possible that there are other advantages of the invention that are not currently recognized but which may become apparent at a later time.
  • While a preferred embodiment of the invention has been described, it should be understood that the invention is not so limited, and modifications may be made without departing from the invention. The scope of the invention is defined by the appended claims, and all devices that come within the meaning of the claims, either literally or by equivalence, are intended to be embraced therein.

Claims (20)

1. A stent assembly, comprising: a catheter, and a stent mounted at a distal end of said catheter, wherein said catheter comprises a conductor contacting said stent and extending longitudinally along at least a portion of said catheter, said conductor being permanently affixed to said catheter.
2. The stent assembly according to claim 1, wherein said conductor comprises conductive ink applied to said catheter.
3. The stent assembly according to claim 2, wherein said conductive ink is applied by pad printing.
4. The stent assembly according to claim 1, wherein said conductor is one of silver-based, platinum-based, gold-based and copper-based.
5. The stent assembly according to claim 1, further comprising a balloon located at said distal end of said catheter, said stent being mounted onto said balloon.
6. The stent assembly according to claim 5, wherein said conductor extends along a portion of said balloon.
7. The stent assembly according to claim 1, wherein said stent is metallic.
8. The stent assembly according to claim 1, wherein said conductor contacts an inner surface of said stent.
9. The stent assembly according to claim 1, wherein said conductor is disposed on an outer surface of said catheter.
10. The stent assembly according to claim 1, wherein said stent is coated with an electrostatically applied coating.
11. The stent assembly according to claim 10, wherein said coating is a drug.
12. The stent assembly according to claim 1, further comprising a balloon located at said distal end of said catheter, said stent being mounted onto said balloon; wherein said conductor comprises conductive ink applied to said catheter; said conductor is disposed on an outer surface of said catheter; said stent is metallic; and said stent is coated with an electrostatically applied coating.
13. The stent assembly according to claim 12, wherein said conductive ink is applied by pad printing; said conductor extends along a portion of said balloon; and said conductor contacts an inner surface of said stent.
14. The stent assembly according to claim 13, wherein said conductor is one of silver-based, platinum-based, gold-based and copper-based, and said coating is a drug.
15. The stent assembly according to claim 1, wherein said conductor comprises conductive ink applied to said catheter, and said conductor is disposed on an outer surface of said catheter.
16. The stent assembly according to claim 1, further comprising a balloon located at said distal end of said catheter, said stent being mounted onto said balloon; wherein said conductor comprises conductive ink applied to said catheter; said conductor is disposed on an outer surface of said catheter; and said conductor extends along a portion of said balloon.
17. A method of coating a stent, comprising:
permanently affixing a conductor to a catheter, said conductor extending along a longitudinal portion of said catheter;
mounting a metallic stent on said catheter, wherein said metallic stent contacts said conductor;
electrically charging a coating material and dispensing said charged coating material in proximity to said metallic stent; and
applying an electrical charge to said conductor, wherein said charged coating material is attracted to said metallic stent, whereby said metallic stent is electrostatically coated with said coating material.
18. The method according to claim 17, wherein said conductor comprises conductive ink applied to said catheter, and said conductor is disposed on an outer surface of said catheter.
19. The method according to claim 18, wherein a balloon is located at a distal end of said catheter, said stent being mounted onto said balloon, and said conductor extends along a portion of said balloon.
20. The method according to claim 19, wherein said conductive ink is applied by pad printing, and said conductor contacts an inner surface of said stent.
US10/738,812 2003-12-16 2003-12-16 Stent catheter with a permanently affixed conductor Abandoned US20050131513A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US10/738,812 US20050131513A1 (en) 2003-12-16 2003-12-16 Stent catheter with a permanently affixed conductor
AU2004305488A AU2004305488B2 (en) 2003-12-16 2004-10-27 Stent catheter with a permanently affixed conductor
PCT/US2004/035632 WO2005060870A2 (en) 2003-12-16 2004-10-27 Stent catheter with a permanently affixed conductor
DK04796535.5T DK1699384T3 (en) 2003-12-16 2004-10-27 STENT CATS WITH A PERMANENT ESTABLISHED LEADER
JP2006545338A JP4563402B2 (en) 2003-12-16 2004-10-27 Stent catheter with permanently attached conductor
EP04796535.5A EP1699384B1 (en) 2003-12-16 2004-10-27 Stent catheter with a permanently affixed conductor
CA2548761A CA2548761C (en) 2003-12-16 2004-10-27 Stent catheter with a permanently affixed conductor
US12/013,927 US7879387B2 (en) 2003-12-16 2008-01-14 Process of electrostatically coating a stent on a catheter

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/738,812 US20050131513A1 (en) 2003-12-16 2003-12-16 Stent catheter with a permanently affixed conductor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/013,927 Division US7879387B2 (en) 2003-12-16 2008-01-14 Process of electrostatically coating a stent on a catheter

Publications (1)

Publication Number Publication Date
US20050131513A1 true US20050131513A1 (en) 2005-06-16

Family

ID=34654264

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/738,812 Abandoned US20050131513A1 (en) 2003-12-16 2003-12-16 Stent catheter with a permanently affixed conductor
US12/013,927 Expired - Lifetime US7879387B2 (en) 2003-12-16 2008-01-14 Process of electrostatically coating a stent on a catheter

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/013,927 Expired - Lifetime US7879387B2 (en) 2003-12-16 2008-01-14 Process of electrostatically coating a stent on a catheter

Country Status (7)

Country Link
US (2) US20050131513A1 (en)
EP (1) EP1699384B1 (en)
JP (1) JP4563402B2 (en)
AU (1) AU2004305488B2 (en)
CA (1) CA2548761C (en)
DK (1) DK1699384T3 (en)
WO (1) WO2005060870A2 (en)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080208313A1 (en) * 2007-02-26 2008-08-28 Medtronic Vascular, Inc. Drug Coated Stent With Magnesium Topcoat
US20100036376A1 (en) * 2004-08-05 2010-02-11 Anderson Neil L Process of Manufacturing a Medical Use Electrical Lead
US20100239635A1 (en) * 2009-03-23 2010-09-23 Micell Technologies, Inc. Drug delivery medical device
US20110072659A1 (en) * 2009-09-30 2011-03-31 John Swanson Medical leads with segmented electrodes and methods of fabrication thereof
WO2012166819A1 (en) * 2011-05-31 2012-12-06 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
US8758429B2 (en) 2005-07-15 2014-06-24 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
US8852625B2 (en) 2006-04-26 2014-10-07 Micell Technologies, Inc. Coatings containing multiple drugs
US8900651B2 (en) 2007-05-25 2014-12-02 Micell Technologies, Inc. Polymer films for medical device coating
US9433516B2 (en) 2007-04-17 2016-09-06 Micell Technologies, Inc. Stents having controlled elution
US9486431B2 (en) 2008-07-17 2016-11-08 Micell Technologies, Inc. Drug delivery medical device
US9510856B2 (en) 2008-07-17 2016-12-06 Micell Technologies, Inc. Drug delivery medical device
US9539593B2 (en) 2006-10-23 2017-01-10 Micell Technologies, Inc. Holder for electrically charging a substrate during coating
US9737642B2 (en) 2007-01-08 2017-08-22 Micell Technologies, Inc. Stents having biodegradable layers
US9789233B2 (en) 2008-04-17 2017-10-17 Micell Technologies, Inc. Stents having bioabsorbable layers
US9981072B2 (en) 2009-04-01 2018-05-29 Micell Technologies, Inc. Coated stents
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
US10232092B2 (en) 2010-04-22 2019-03-19 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
US10272606B2 (en) 2013-05-15 2019-04-30 Micell Technologies, Inc. Bioabsorbable biomedical implants
US10315217B2 (en) * 2014-06-18 2019-06-11 Kaneka Corporation Method for manufacturing elastic tubular body
CN109875486A (en) * 2019-03-12 2019-06-14 刘海鹏 A kind of visualization biliary tract sound and its application method
US10835396B2 (en) 2005-07-15 2020-11-17 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
US11039943B2 (en) 2013-03-12 2021-06-22 Micell Technologies, Inc. Bioabsorbable biomedical implants
US11369498B2 (en) 2010-02-02 2022-06-28 MT Acquisition Holdings LLC Stent and stent delivery system with improved deliverability
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
US11904118B2 (en) 2010-07-16 2024-02-20 Micell Medtech Inc. Drug delivery medical device

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8458879B2 (en) * 2001-07-03 2013-06-11 Advanced Bio Prosthetic Surfaces, Ltd., A Wholly Owned Subsidiary Of Palmaz Scientific, Inc. Method of fabricating an implantable medical device
FR2896698B1 (en) 2006-02-02 2008-09-19 Vygon Sa NEUROSTIMULATION CATHETER AND ITS BASE
AU2009288566A1 (en) * 2008-08-26 2010-03-11 Trutek Corp. Electrostatically charged mask filter products and method for increased filtration efficiency
EP3291729B1 (en) 2015-05-07 2020-05-13 Ecom Medical, Inc. Method for fabricating invasive ecg probe
JP7073338B2 (en) * 2017-03-16 2022-05-23 テルモ株式会社 Balloon catheter and its manufacturing method and manufacturing equipment
WO2020165987A1 (en) * 2019-02-14 2020-08-20 アネスト岩田株式会社 Electrostatic spraying method and electrostatic spraying device used for electrostatic spraying method

Citations (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3468271A (en) * 1966-09-02 1969-09-23 William Birch Eng Ltd Sewing machines
US4270449A (en) * 1978-03-02 1981-06-02 Toppan Printing Co., Ltd. Method of printing plastic surfaces
US4749125A (en) * 1987-01-16 1988-06-07 Terronics Development Corp. Nozzle method and apparatus
US4930494A (en) * 1988-03-09 1990-06-05 Olympus Optical Co., Ltd. Apparatus for bending an insertion section of an endoscope using a shape memory alloy
US5086973A (en) * 1990-04-11 1992-02-11 Terronics Development Corp. Nozzle modulators
US5166601A (en) * 1990-06-28 1992-11-24 U.S. Philips Corp. Test device for electric circuits on boards
US5332154A (en) * 1992-02-28 1994-07-26 Lundy And Associates Shoot-up electrostatic nozzle and method
US5431638A (en) * 1991-04-10 1995-07-11 United States Surgical Corporation Energy dissipation device
US5609629A (en) * 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
US5634476A (en) * 1992-03-17 1997-06-03 Fredric I. Orkin Uterine contraction sensing device and method for manufacture and use thereof
US5681308A (en) * 1994-06-24 1997-10-28 Stuart D. Edwards Ablation apparatus for cardiac chambers
US5807306A (en) * 1992-11-09 1998-09-15 Cortrak Medical, Inc. Polymer matrix drug delivery apparatus
US5938623A (en) * 1994-10-28 1999-08-17 Intella Interventional Systems Guide wire with adjustable stiffness
US5944710A (en) * 1996-06-24 1999-08-31 Genetronics, Inc. Electroporation-mediated intravascular delivery
US6032061A (en) * 1997-02-20 2000-02-29 Boston Scientifc Corporation Catheter carrying an electrode and methods of assembly
US6091980A (en) * 1998-05-12 2000-07-18 Massachusetts Institute Of Technology Stent slip sensing system and method
US6156028A (en) * 1994-03-21 2000-12-05 Prescott; Marvin A. Method and apparatus for therapeutic laser treatment of wounds
US6245020B1 (en) * 1998-01-26 2001-06-12 Scimed Life System, Inc. Catheter assembly with distal end inductive coupler and embedded transmission line
US6256525B1 (en) * 1998-02-27 2001-07-03 Ep Technologies, Inc. Catheter distal end assemblies with bonded surface coatings
US6299604B1 (en) * 1998-08-20 2001-10-09 Cook Incorporated Coated implantable medical device
US20010032013A1 (en) * 1999-11-19 2001-10-18 Denes Marton Self-supporting laminated films, structural materials and medical devices manufactured therefrom and method of making same
US6308097B1 (en) * 1994-10-24 2001-10-23 Transscan Medical Ltd. Tissue characterization based on impedance images and on impedance measurements
US6347247B1 (en) * 1998-05-08 2002-02-12 Genetronics Inc. Electrically induced vessel vasodilation
US20020026236A1 (en) * 2000-01-25 2002-02-28 Helmus Michael N. Delivery systems for periadventitial delivery for treatment of restenosis and anastomotic intimal hyperplasia
US6355058B1 (en) * 1999-12-30 2002-03-12 Advanced Cardiovascular Systems, Inc. Stent with radiopaque coating consisting of particles in a binder
US6356779B1 (en) * 1999-06-04 2002-03-12 3M Innovative Properties Company Universally functional biomedical electrode
US6357447B1 (en) * 1993-10-15 2002-03-19 Ep Technologies, Inc. Surface coatings for catheters, direct contacting diagnostic and therapeutic devices
US6364902B1 (en) * 1998-10-05 2002-04-02 Noble-Met, Ltd. Metal composite tube for biomedical applications
US6368658B1 (en) * 1999-04-19 2002-04-09 Scimed Life Systems, Inc. Coating medical devices using air suspension
US20020045668A1 (en) * 2000-07-17 2002-04-18 Wenbin Dang Compositions for sustained release of analgesic agents, and methods of making and using the same
US6394949B1 (en) * 1998-10-05 2002-05-28 Scimed Life Systems, Inc. Large area thermal ablation
US6409716B1 (en) * 1989-12-15 2002-06-25 Scimed Life Systems, Inc. Drug delivery
US6416505B1 (en) * 1998-05-05 2002-07-09 Scimed Life Systems, Inc. Surgical method and apparatus for positioning a diagnostic or therapeutic element within the body and pressure application probe for use with same
US6421556B2 (en) * 1995-07-28 2002-07-16 Scimed Life Systems, Inc. Systems and methods for conducting electrophysiological testing using high-voltage energy pulses to stun tissue
US20020103445A1 (en) * 2000-08-24 2002-08-01 Rahdert David A. Thermography catheter with flexible circuit temperature sensors
US6428537B1 (en) * 1998-05-22 2002-08-06 Scimed Life Systems, Inc. Electrophysiological treatment methods and apparatus employing high voltage pulse to render tissue temporarily unresponsive
US6440488B2 (en) * 1999-12-03 2002-08-27 Ep Medsystems, Inc. Flexible electrode catheter and process for manufacturing the same
US20020128640A1 (en) * 2001-03-07 2002-09-12 Scimed Life Systems, Inc. Internal indifferent electrode device for use with lesion creation apparatus and method of forming lesions using the same
US20020133224A1 (en) * 2001-03-13 2002-09-19 Clara Bajgar Drug eluting encapsulated stent
US6463323B1 (en) * 1998-11-12 2002-10-08 Em Vascular, Inc. Electrically mediated angiogenesis
US6468272B1 (en) * 1997-10-10 2002-10-22 Scimed Life Systems, Inc. Surgical probe for supporting diagnostic and therapeutic elements in contact with tissue in or around body orifices
US20020172829A1 (en) * 1997-02-28 2002-11-21 Yuichi Mori Coating composition, coating product and coating method
US20020177899A1 (en) * 1999-11-03 2002-11-28 Eum Jay J. Method of loading a stent on a delivery catheter
US20020188324A1 (en) * 2001-05-11 2002-12-12 Blinn Stephen M. Method and system for improving the effectiveness of medical devices by adhering drugs to the surface thereof
US6500144B1 (en) * 2000-09-15 2002-12-31 Scimed Life Systems, Inc. Steerable catheter and self-mounting center support for use with same
US20030003221A1 (en) * 2001-07-02 2003-01-02 Zhong Sheng-Ping (Samuel) Coating dispensing system and method using a solenoid head for coating medical devices
US20030018381A1 (en) * 2000-01-25 2003-01-23 Scimed Life Systems, Inc. Manufacturing medical devices by vapor deposition
US6511478B1 (en) * 2000-06-30 2003-01-28 Scimed Life Systems, Inc. Medical probe with reduced number of temperature sensor wires
US6529756B1 (en) * 1999-11-22 2003-03-04 Scimed Life Systems, Inc. Apparatus for mapping and coagulating soft tissue in or around body orifices
US20030054090A1 (en) * 2001-09-18 2003-03-20 Henrik Hansen Method for spray-coating medical devices
US6537310B1 (en) * 1999-11-19 2003-03-25 Advanced Bio Prosthetic Surfaces, Ltd. Endoluminal implantable devices and method of making same
US6575966B2 (en) * 1999-08-23 2003-06-10 Cryocath Technologies Inc. Endovascular cryotreatment catheter
US6579690B1 (en) * 1997-12-05 2003-06-17 Therasense, Inc. Blood analyte monitoring through subcutaneous measurement
US6589546B2 (en) * 1998-08-28 2003-07-08 Scimed Life Systems, Inc. Polymeric coatings for controlled delivery of active agents
US20030130615A1 (en) * 2000-03-23 2003-07-10 Scimed Life Systems, Inc. Pressure sensor for therapeutic delivery device and method
US6596699B2 (en) * 1998-09-22 2003-07-22 Biosurface Engineering Technologies, Inc. Nucleic acid coating compositions and methods
US6607598B2 (en) * 1999-04-19 2003-08-19 Scimed Life Systems, Inc. Device for protecting medical devices during a coating process
US20030158548A1 (en) * 2002-02-19 2003-08-21 Phan Huy D. Surgical system including clamp and apparatus for securing an energy transmission device to the clamp and method of converting a clamp into an electrophysiology device
US6610055B1 (en) * 1997-10-10 2003-08-26 Scimed Life Systems, Inc. Surgical method for positioning a diagnostic or therapeutic element on the epicardium or other organ surface
US6613046B1 (en) * 1999-11-22 2003-09-02 Scimed Life Systems, Inc. Loop structures for supporting diagnostic and therapeutic elements in contact with body tissue
US20030185964A1 (en) * 2002-03-28 2003-10-02 Jan Weber Method for spray-coating a medical device having a tubular wall such as a stent
US20030204238A1 (en) * 2002-04-26 2003-10-30 Eugene Tedeschi Coated stent with crimpable coating
US6749628B1 (en) * 2001-05-17 2004-06-15 Advanced Cardiovascular Systems, Inc. Stent and catheter assembly and method for treating bifurcations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2555393B2 (en) * 1988-01-08 1996-11-20 勝史 吉田 Stenosis vessel treatment tool
US5304121A (en) * 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5165601A (en) * 1990-04-11 1992-11-24 Terronics Development Corporation Nozzle for low resistivity flowable material
US5305320A (en) 1992-10-06 1994-04-19 At&T Bell Laboratories Peripheral communications network
GB9616267D0 (en) 1996-08-02 1996-09-11 Ranier Ltd Balloon catheter
EP1003080B1 (en) * 1998-11-18 2008-01-30 Canon Kabushiki Kaisha Toner, and process for producing toner
US6648879B2 (en) * 1999-02-24 2003-11-18 Cryovascular Systems, Inc. Safety cryotherapy catheter
US6468271B1 (en) 1999-02-24 2002-10-22 Scimed Life Systems, Inc. Device and method for percutaneous myocardial revascularization
US6364903B2 (en) 1999-03-19 2002-04-02 Meadox Medicals, Inc. Polymer coated stent
US6786889B1 (en) 1999-03-31 2004-09-07 Scimed Life Systems, Inc Textured and/or marked balloon for stent delivery
EP1190252B1 (en) 1999-04-28 2008-12-31 Eidgenössische Technische Hochschule Zürich Polyionic coatings in analytic and sensor devices
GB9920112D0 (en) * 1999-08-26 1999-10-27 Aortech Int Plc Improvements relating to catheters (I)
JP2002345972A (en) * 2001-05-30 2002-12-03 Kaneka Medix Corp Stent and method of manufacturing for the same

Patent Citations (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3468271A (en) * 1966-09-02 1969-09-23 William Birch Eng Ltd Sewing machines
US4270449A (en) * 1978-03-02 1981-06-02 Toppan Printing Co., Ltd. Method of printing plastic surfaces
US4749125A (en) * 1987-01-16 1988-06-07 Terronics Development Corp. Nozzle method and apparatus
US4930494A (en) * 1988-03-09 1990-06-05 Olympus Optical Co., Ltd. Apparatus for bending an insertion section of an endoscope using a shape memory alloy
US6409716B1 (en) * 1989-12-15 2002-06-25 Scimed Life Systems, Inc. Drug delivery
US5086973A (en) * 1990-04-11 1992-02-11 Terronics Development Corp. Nozzle modulators
US5166601A (en) * 1990-06-28 1992-11-24 U.S. Philips Corp. Test device for electric circuits on boards
US5431638A (en) * 1991-04-10 1995-07-11 United States Surgical Corporation Energy dissipation device
US5332154A (en) * 1992-02-28 1994-07-26 Lundy And Associates Shoot-up electrostatic nozzle and method
US5634476A (en) * 1992-03-17 1997-06-03 Fredric I. Orkin Uterine contraction sensing device and method for manufacture and use thereof
US5807306A (en) * 1992-11-09 1998-09-15 Cortrak Medical, Inc. Polymer matrix drug delivery apparatus
US6357447B1 (en) * 1993-10-15 2002-03-19 Ep Technologies, Inc. Surface coatings for catheters, direct contacting diagnostic and therapeutic devices
US6156028A (en) * 1994-03-21 2000-12-05 Prescott; Marvin A. Method and apparatus for therapeutic laser treatment of wounds
US5681308A (en) * 1994-06-24 1997-10-28 Stuart D. Edwards Ablation apparatus for cardiac chambers
US6308097B1 (en) * 1994-10-24 2001-10-23 Transscan Medical Ltd. Tissue characterization based on impedance images and on impedance measurements
US5938623A (en) * 1994-10-28 1999-08-17 Intella Interventional Systems Guide wire with adjustable stiffness
US6096070A (en) * 1995-06-07 2000-08-01 Med Institute Inc. Coated implantable medical device
US5609629A (en) * 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
US6421556B2 (en) * 1995-07-28 2002-07-16 Scimed Life Systems, Inc. Systems and methods for conducting electrophysiological testing using high-voltage energy pulses to stun tissue
US5944710A (en) * 1996-06-24 1999-08-31 Genetronics, Inc. Electroporation-mediated intravascular delivery
US6032061A (en) * 1997-02-20 2000-02-29 Boston Scientifc Corporation Catheter carrying an electrode and methods of assembly
US20020172829A1 (en) * 1997-02-28 2002-11-21 Yuichi Mori Coating composition, coating product and coating method
US6468272B1 (en) * 1997-10-10 2002-10-22 Scimed Life Systems, Inc. Surgical probe for supporting diagnostic and therapeutic elements in contact with tissue in or around body orifices
US6610055B1 (en) * 1997-10-10 2003-08-26 Scimed Life Systems, Inc. Surgical method for positioning a diagnostic or therapeutic element on the epicardium or other organ surface
US6579690B1 (en) * 1997-12-05 2003-06-17 Therasense, Inc. Blood analyte monitoring through subcutaneous measurement
US6450965B2 (en) * 1998-01-26 2002-09-17 Scimed Life Systems, Inc. Imaging catheter assembly with distal end inductive coupler and embedded transmission line
US6245020B1 (en) * 1998-01-26 2001-06-12 Scimed Life System, Inc. Catheter assembly with distal end inductive coupler and embedded transmission line
US6256525B1 (en) * 1998-02-27 2001-07-03 Ep Technologies, Inc. Catheter distal end assemblies with bonded surface coatings
US6416505B1 (en) * 1998-05-05 2002-07-09 Scimed Life Systems, Inc. Surgical method and apparatus for positioning a diagnostic or therapeutic element within the body and pressure application probe for use with same
US6347247B1 (en) * 1998-05-08 2002-02-12 Genetronics Inc. Electrically induced vessel vasodilation
US6091980A (en) * 1998-05-12 2000-07-18 Massachusetts Institute Of Technology Stent slip sensing system and method
US6428537B1 (en) * 1998-05-22 2002-08-06 Scimed Life Systems, Inc. Electrophysiological treatment methods and apparatus employing high voltage pulse to render tissue temporarily unresponsive
US6299604B1 (en) * 1998-08-20 2001-10-09 Cook Incorporated Coated implantable medical device
US6589546B2 (en) * 1998-08-28 2003-07-08 Scimed Life Systems, Inc. Polymeric coatings for controlled delivery of active agents
US6596699B2 (en) * 1998-09-22 2003-07-22 Biosurface Engineering Technologies, Inc. Nucleic acid coating compositions and methods
US6394949B1 (en) * 1998-10-05 2002-05-28 Scimed Life Systems, Inc. Large area thermal ablation
US6364902B1 (en) * 1998-10-05 2002-04-02 Noble-Met, Ltd. Metal composite tube for biomedical applications
US6463323B1 (en) * 1998-11-12 2002-10-08 Em Vascular, Inc. Electrically mediated angiogenesis
US6607598B2 (en) * 1999-04-19 2003-08-19 Scimed Life Systems, Inc. Device for protecting medical devices during a coating process
US6368658B1 (en) * 1999-04-19 2002-04-09 Scimed Life Systems, Inc. Coating medical devices using air suspension
US6356779B1 (en) * 1999-06-04 2002-03-12 3M Innovative Properties Company Universally functional biomedical electrode
US6575966B2 (en) * 1999-08-23 2003-06-10 Cryocath Technologies Inc. Endovascular cryotreatment catheter
US20020177899A1 (en) * 1999-11-03 2002-11-28 Eum Jay J. Method of loading a stent on a delivery catheter
US20010032013A1 (en) * 1999-11-19 2001-10-18 Denes Marton Self-supporting laminated films, structural materials and medical devices manufactured therefrom and method of making same
US6537310B1 (en) * 1999-11-19 2003-03-25 Advanced Bio Prosthetic Surfaces, Ltd. Endoluminal implantable devices and method of making same
US6529756B1 (en) * 1999-11-22 2003-03-04 Scimed Life Systems, Inc. Apparatus for mapping and coagulating soft tissue in or around body orifices
US6613046B1 (en) * 1999-11-22 2003-09-02 Scimed Life Systems, Inc. Loop structures for supporting diagnostic and therapeutic elements in contact with body tissue
US6440488B2 (en) * 1999-12-03 2002-08-27 Ep Medsystems, Inc. Flexible electrode catheter and process for manufacturing the same
US6355058B1 (en) * 1999-12-30 2002-03-12 Advanced Cardiovascular Systems, Inc. Stent with radiopaque coating consisting of particles in a binder
US20030018381A1 (en) * 2000-01-25 2003-01-23 Scimed Life Systems, Inc. Manufacturing medical devices by vapor deposition
US20020026236A1 (en) * 2000-01-25 2002-02-28 Helmus Michael N. Delivery systems for periadventitial delivery for treatment of restenosis and anastomotic intimal hyperplasia
US20030130615A1 (en) * 2000-03-23 2003-07-10 Scimed Life Systems, Inc. Pressure sensor for therapeutic delivery device and method
US6511478B1 (en) * 2000-06-30 2003-01-28 Scimed Life Systems, Inc. Medical probe with reduced number of temperature sensor wires
US20020045668A1 (en) * 2000-07-17 2002-04-18 Wenbin Dang Compositions for sustained release of analgesic agents, and methods of making and using the same
US20020103445A1 (en) * 2000-08-24 2002-08-01 Rahdert David A. Thermography catheter with flexible circuit temperature sensors
US6500144B1 (en) * 2000-09-15 2002-12-31 Scimed Life Systems, Inc. Steerable catheter and self-mounting center support for use with same
US20020128640A1 (en) * 2001-03-07 2002-09-12 Scimed Life Systems, Inc. Internal indifferent electrode device for use with lesion creation apparatus and method of forming lesions using the same
US20020133224A1 (en) * 2001-03-13 2002-09-19 Clara Bajgar Drug eluting encapsulated stent
US20020188324A1 (en) * 2001-05-11 2002-12-12 Blinn Stephen M. Method and system for improving the effectiveness of medical devices by adhering drugs to the surface thereof
US6749628B1 (en) * 2001-05-17 2004-06-15 Advanced Cardiovascular Systems, Inc. Stent and catheter assembly and method for treating bifurcations
US20030003221A1 (en) * 2001-07-02 2003-01-02 Zhong Sheng-Ping (Samuel) Coating dispensing system and method using a solenoid head for coating medical devices
US20030054090A1 (en) * 2001-09-18 2003-03-20 Henrik Hansen Method for spray-coating medical devices
US20030158548A1 (en) * 2002-02-19 2003-08-21 Phan Huy D. Surgical system including clamp and apparatus for securing an energy transmission device to the clamp and method of converting a clamp into an electrophysiology device
US20030185964A1 (en) * 2002-03-28 2003-10-02 Jan Weber Method for spray-coating a medical device having a tubular wall such as a stent
US20030204238A1 (en) * 2002-04-26 2003-10-30 Eugene Tedeschi Coated stent with crimpable coating

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8286338B2 (en) * 2004-08-05 2012-10-16 Cathrx Ltd Process of manufacturing a medical use electrical lead
US20100036376A1 (en) * 2004-08-05 2010-02-11 Anderson Neil L Process of Manufacturing a Medical Use Electrical Lead
US10668275B2 (en) 2004-08-05 2020-06-02 Cathrx Ltd Electrical leads for medical use
US10898353B2 (en) 2005-07-15 2021-01-26 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
US9827117B2 (en) 2005-07-15 2017-11-28 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
US8758429B2 (en) 2005-07-15 2014-06-24 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
US10835396B2 (en) 2005-07-15 2020-11-17 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
US11911301B2 (en) 2005-07-15 2024-02-27 Micell Medtech Inc. Polymer coatings containing drug powder of controlled morphology
US9737645B2 (en) 2006-04-26 2017-08-22 Micell Technologies, Inc. Coatings containing multiple drugs
US11850333B2 (en) 2006-04-26 2023-12-26 Micell Medtech Inc. Coatings containing multiple drugs
US11007307B2 (en) 2006-04-26 2021-05-18 Micell Technologies, Inc. Coatings containing multiple drugs
US9415142B2 (en) 2006-04-26 2016-08-16 Micell Technologies, Inc. Coatings containing multiple drugs
US8852625B2 (en) 2006-04-26 2014-10-07 Micell Technologies, Inc. Coatings containing multiple drugs
US9539593B2 (en) 2006-10-23 2017-01-10 Micell Technologies, Inc. Holder for electrically charging a substrate during coating
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
US9737642B2 (en) 2007-01-08 2017-08-22 Micell Technologies, Inc. Stents having biodegradable layers
US10617795B2 (en) 2007-01-08 2020-04-14 Micell Technologies, Inc. Stents having biodegradable layers
US8273402B2 (en) * 2007-02-26 2012-09-25 Medtronic Vascular, Inc. Drug coated stent with magnesium topcoat
US20080208313A1 (en) * 2007-02-26 2008-08-28 Medtronic Vascular, Inc. Drug Coated Stent With Magnesium Topcoat
US9486338B2 (en) 2007-04-17 2016-11-08 Micell Technologies, Inc. Stents having controlled elution
US9433516B2 (en) 2007-04-17 2016-09-06 Micell Technologies, Inc. Stents having controlled elution
US9775729B2 (en) 2007-04-17 2017-10-03 Micell Technologies, Inc. Stents having controlled elution
US8900651B2 (en) 2007-05-25 2014-12-02 Micell Technologies, Inc. Polymer films for medical device coating
US10350333B2 (en) 2008-04-17 2019-07-16 Micell Technologies, Inc. Stents having bioabsorable layers
US9789233B2 (en) 2008-04-17 2017-10-17 Micell Technologies, Inc. Stents having bioabsorbable layers
US9510856B2 (en) 2008-07-17 2016-12-06 Micell Technologies, Inc. Drug delivery medical device
US9486431B2 (en) 2008-07-17 2016-11-08 Micell Technologies, Inc. Drug delivery medical device
US9981071B2 (en) 2008-07-17 2018-05-29 Micell Technologies, Inc. Drug delivery medical device
US10350391B2 (en) 2008-07-17 2019-07-16 Micell Technologies, Inc. Drug delivery medical device
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
US20100239635A1 (en) * 2009-03-23 2010-09-23 Micell Technologies, Inc. Drug delivery medical device
US9981072B2 (en) 2009-04-01 2018-05-29 Micell Technologies, Inc. Coated stents
US10653820B2 (en) 2009-04-01 2020-05-19 Micell Technologies, Inc. Coated stents
US8925191B2 (en) 2009-09-30 2015-01-06 Advanced Neuromodulation Systems, Inc. Method of fabricating a stimulation lead
US8171621B2 (en) * 2009-09-30 2012-05-08 Advanced Neuromodulation Systems, Inc. Methods of fabrication of a simulation lead
US20110072659A1 (en) * 2009-09-30 2011-03-31 John Swanson Medical leads with segmented electrodes and methods of fabrication thereof
US11369498B2 (en) 2010-02-02 2022-06-28 MT Acquisition Holdings LLC Stent and stent delivery system with improved deliverability
US9687864B2 (en) 2010-03-26 2017-06-27 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
US10232092B2 (en) 2010-04-22 2019-03-19 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
US11904118B2 (en) 2010-07-16 2024-02-20 Micell Medtech Inc. Drug delivery medical device
US10464100B2 (en) 2011-05-31 2019-11-05 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
WO2012166819A1 (en) * 2011-05-31 2012-12-06 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
US10729819B2 (en) 2011-07-15 2020-08-04 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
US11039943B2 (en) 2013-03-12 2021-06-22 Micell Technologies, Inc. Bioabsorbable biomedical implants
US10272606B2 (en) 2013-05-15 2019-04-30 Micell Technologies, Inc. Bioabsorbable biomedical implants
US10315217B2 (en) * 2014-06-18 2019-06-11 Kaneka Corporation Method for manufacturing elastic tubular body
CN109875486A (en) * 2019-03-12 2019-06-14 刘海鹏 A kind of visualization biliary tract sound and its application method

Also Published As

Publication number Publication date
CA2548761A1 (en) 2005-07-07
EP1699384B1 (en) 2015-05-06
JP2007534362A (en) 2007-11-29
JP4563402B2 (en) 2010-10-13
AU2004305488B2 (en) 2010-09-30
WO2005060870A2 (en) 2005-07-07
EP1699384A2 (en) 2006-09-13
WO2005060870A3 (en) 2005-12-08
CA2548761C (en) 2012-05-15
DK1699384T3 (en) 2015-07-27
US7879387B2 (en) 2011-02-01
US20080113084A1 (en) 2008-05-15
AU2004305488A1 (en) 2005-07-07

Similar Documents

Publication Publication Date Title
US7879387B2 (en) Process of electrostatically coating a stent on a catheter
JP4344384B2 (en) Method and system for treating side branch ostium
US20040230176A1 (en) System for treating a vascular condition that inhibits restenosis at stent ends
US7861570B2 (en) Stent with improved drug loading capacity
US7208008B2 (en) Balloonless direct stenting device
US7470281B2 (en) Coated stent with crimpable coating
EP1534181B1 (en) Centering catheter
JP4394461B2 (en) Overlapping covered stent
EP1755485B1 (en) Method and system for stent retention using an adhesive
EP2234664B1 (en) Methods for incorporating a drug into an elastomeric medical device
US20030139801A1 (en) Delivery of therapeutic capable agents
US20040147998A1 (en) Differentially coated stent
US20060155370A1 (en) Stent with intermittent coating
EP1680153B1 (en) Natural tissue stent
US20050182474A1 (en) Coated stent having protruding crowns and elongated struts
WO2012132801A1 (en) Stent and stent delivery system
US20040215314A1 (en) Stent deployment assembly with collars for drug-eluting stent
US10076426B2 (en) Stent and stent delivery system
WO2021035683A1 (en) Balloon stent

Legal Events

Date Code Title Description
AS Assignment

Owner name: COOK INCORPORATED, INDIANA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MYERS, RANDY JOE;REEL/FRAME:014823/0871

Effective date: 20031119

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION